NEWSLETTER

By clicking submit, you agree to share your email address with TFN to receive marketing, updates, and other emails from the site owner. Use the unsubscribe link in the emails to opt out at any time.

Ada Ventures and Illumina Accelerator back Juno Bio’s $3.8M round to scale vaginal microbiome testing

Juno Bio founders
Image credits: Juno Bio
  • Juno Bio has raised $3.8 million from Ada Ventures, Artesian, Entrepreneur First, and Illumina Accelerator to scale precision vaginal microbiome testing.
  • The Oakland-based startup says 67.5% of patients who later used its platform had previously been misdiagnosed, underdiagnosed, or overdiagnosed.
  • The capital funds Juno Bio’s first CLIA-certified sequencing lab, dedicated entirely to women’s health, now live in Oakland, California.

A doctor’s visit for a vaginal infection often ends the same way it started: a swab under a microscope, a guess, and a prescription that may or may not work. Juno Bio, a women’s health startup built on the belief that the real failure in vaginal healthcare is diagnostic rather than therapeutic, has raised $3.8 million to change that. 

The round comes from Ada Ventures, Artesian, Entrepreneur First, and Illumina Accelerator, and coincides with Juno Bio opening its first CLIA-certified sequencing lab in Oakland, California, a facility dedicated entirely to women’s health, processing tests that were previously outsourced.

The biggest challenge of getting the diagnosis right

Hana Janebdar co-founded Juno Bio in 2018 with Dr. Leighton Turner, starting from a simple observation: the vaginal microbiome had been almost entirely ignored by mainstream diagnostics, despite driving conditions that send millions of women to the doctor every year. 

According to the company’s own clinical data, 67.5% of patients who later used its platform had been misdiagnosed, underdiagnosed, or overdiagnosed before switching to Juno Bio, and only 13% had been successfully treated. Roughly half had co-infections that conventional testing missed entirely. 

Where a standard clinical test checks for a handful of pathogens, Juno Bio’s next-generation sequencing platform screens for around 10,000 bacteria and fungi alongside four common STIs, aiming to help clinicians tell apart conditions that look identical under a microscope: bacterial vaginosis, yeast infections, aerobic vaginitis, cytolytic vaginosis, and hormone-driven changes.

The competitive landscape of precision diagnostics

Juno Bio isn’t alone in this space. Evvy, a New York-based rival, has raised $19 million to date, including a $14 million Series A led by Left Lane Capital, and also uses metagenomic sequencing for vaginal microbiome testing. Daye, meanwhile, is pushing into diagnostics through a tampon-based collection method. 

Where those two lean toward consumer wellness and virtual care, Juno Bio is positioning itself as a clinical infrastructure, a data layer that other providers and pharmaceutical researchers can build on, rather than a direct-to-consumer wellness brand.

That distinction matters for the funding thesis. “What they’ve built at this stage, with this level of capital efficiency, is exceptional. We’re proud to support the team as they scale their clinical infrastructure and continue leading innovation in this critically underserved category,” says Check Warner, co-founding partner at Ada Ventures.

Janebdar frames the round as a scaling moment rather than a pivot: “This next chapter is about scaling that work, expanding access to more actionable care, and continuing to close the gender health gap. We’re incredibly grateful to our investors and partners for their trust in our team and our vision as we move into this next stage of growth.”

Since its first consumer test, Juno Bio has sold more than 20,000 kits and built one of the largest vaginal microbiome datasets in the field, expanding from wellness into clinical diagnostics, pharmaceutical research partnerships, telehealth, and pharmacy integrations. The new test is the company’s first designed explicitly to inform clinical decisions rather than just consumer curiosity.

Can it close women’s healthcare’s diagnostic gap?

The wager behind the round is that underinvestment in women’s health is now a correctable market failure rather than a permanent one. The global precision medicine market is projected to grow from roughly $112 billion in 2025 to more than $207 billion by 2030, according to Grand View Research, with genomics and personalised diagnostics as key drivers. Fertility, menopause, and reproductive health are increasingly where investors expect that growth to concentrate.

Whether sequencing-grade diagnostics can actually move the needle on a 67.5% misdiagnosis rate at scale, across a healthcare system that still defaults to the microscope and the whiff test, is the open question. Juno Bio’s bet is that better data is the treatment healthcare has been missing all along.

Total
0
Shares
Related Posts
Total
0
Share
tfn-logo-2-220x220-removebg-preview

Get daily funding news briefings in the tech world delivered right to your inbox.

Enter Your Email
join our newsletter. thank you
TFN Banner